Health News Roundup: India's Serum looks beyond COVID with new vaccines for malaria, dengue; US officials urge UnitedHealth to expedite payments to providers

Officials from the U.S. Department of Labor and the U.S. Department of Health and Human Services urged UnitedHealth (UHG)to take "responsibility to ensure no provider is compromised by their cash flow challenges stemming from this cyberattack on Change Healthcare." India's Serum looks beyond COVID with new vaccines for malaria, dengue The CEO of the world's biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations.

Health News Roundup: India's Serum looks beyond COVID with new vaccines for malaria, dengue; US officials urge UnitedHealth to expedite payments to providers
Representative Image Image Credit: ANI

Following is a summary of current health news briefs.

US officials urge UnitedHealth to expedite payments to providers

Officials from the U.S. government asked UnitedHealth Group to expedite payments to healthcare providers in an open letter on Sunday, after a hack of the insurer's Change Healthcare tech unit crippled medical claims and payments. Officials from the U.S. Department of Labor and the U.S. Department of Health and Human Services urged UnitedHealth (UHG)to take "responsibility to ensure no provider is compromised by their cash flow challenges stemming from this cyberattack on Change Healthcare."

India's Serum looks beyond COVID with new vaccines for malaria, dengue

The CEO of the world's biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations. With COVID manufacturing scaled back as demand ebbs, the company is using those facilities to instead manufacture its newer shots, which it estimates will boost total production by two and a half billion doses, CEO Adar Poonawalla said in an interview.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.